Abstract
Elsewhere in this issue a group of investigators have presented a summary of their studies on attenuated measles vaccine together with their evaluation of the present status of this exciting development in immunization. This short paper, one of eight appearing in a recent issue of The New England Journal of Medicine devoted in its entirety to studies on attenuated measles vaccine, represents the cooperative studies of a number of investigators who have in a unique way combined their efforts to provide a carefully planned evaluation of a live attenuated measles virus vaccine first developed by Dr. John F. Enders and his associates between 1954 and 1958. In short, this live modified virus vaccine, requiring a single subcutaneous injection of 0.2 ml., results in a 2- to-3-day febrile illness from 7 to 8 days after inoculation. The mean maximum fever is 102.4 F by rectum, but there is apparent well-being in
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
